LAWSUITS NEWS & LEGAL INFORMATION
Search Results for
Sort by date 131 pages found matching Glaxo- Fixodent Zinc Poisoning: "They Don't Tell You How Much Is Too Much"
Oct-6-10 Broadview, SK Hedvig Ahlquist, a 56-year-old nurse from Saskatchewan, is leading a class-action lawsuit in Canada against two denture adhesive manufacturers that could potentially extend across the entire Great White North. According to the Canadian Press ( CP ), lawyers have filed statements of claim against GlaxoSmithKline and Proctor and Gamble in... - More Damning News about Avandia One Month before FDA Review
Jun-13-10 Washington, DC A well-known and outspoken reviewer for the US Food and Drug Administration (FDA) has released study data suggesting that type 2 diabetes drug Avandia increases the risk of heart attack by 25 percent, the risk of stroke by 27 percent and the risk of death by as much as 17 percent when compared with rival diabetes drug Actos, manufactured... - UK Women Still in the Dark About SSRI Birth Defect Risk
Aug-8-09 Bangor, Wales It will be two years next month that a study of nearly 500,000 women by researchers at the University of Pittsburgh Medical Center revealed nearly half of women taking an ssri antidepressant had no idea their medication could cause SSRI birth defects . Women in the US aren't unique in that risk. Dr. Tim Kendall, joint director of the U... - New Study Re-affirms Paxil Causes Birth Defects
Dec-7-08 Washington, DC Various Paxil defects , including those associated with newborns, have been known since September 2005. That's when studies first surfaced that suggested a link between the antidepressant and Paxil birth defects. In response the US Food and Drug Administration (FDA) mandated GlaxoSmithKline to update product labeling for birth defects, and... - Avandia: More Questions About Tim Russert
Jul-2-08 Washington, DC In an apparent attempt to put an end to the sugarcoating of the diabetes drug industry, and in the aftermath of Avandia , the US Food and Drug Administration (FDA) has just wrapped up a two-day meeting of the minds to vet the possibility that standards should be changed. That's because two large scientific studies found no evidence that... - Lawmakers Warn Drug Makers To Knock It Off After Avandia Debacle - Part II
Nov-22-07 Washington, DC: On November 14, 2007, the FDA added a new black box warning to GlaxoSmithKline's diabetes drug Avandia , about a potential increased risk of heart attacks, in addition to the black box warning that was added in August 2007, about the increased risk of heart failure. The FDA said the new warning would also apply to Glaxo's diabetes drugs... - Avandia Debacle Exposes Big Pharma's FDA Mole
Aug-6-07 Washington, DC: In May 2007, FDA spokesperson Douglas Arbesfeld made headlines when he waged a smear campaign against cardiologist Dr Steve Nissen, after his study in the New England Journal of Medicine showed the diabetes drug Avandia, sold by GlaxoSmithKline, allegedly increased the risk of heart attacks by 43% and cardiovascular deaths by possibly 64%... - Avandia Defended by Glaxo Despite Heart Attack Risk
Aug-2-07 Rockville, MD As part of the July 30th proceedings of a federal drug advisory committee that ultimately voted to keep Avandia on the market despite cardiovascular risk, Avandia maker GlaxoSmithKline defended its product as completely safe. Dr. Murray Stewart, A Vice President with the company, presented the findings of an examination of data from more... - FDA Scientist Graham Calls Glaxo Avandia Trial Useless
Jul-30-07 Washington, DC: World-renowned cardiologist Dr Steven Nissen and statistician Kathy Wolski of the Cleveland Clinic posted a study online on May 21, 2007, to warn the public that the diabetes drug Avandia (rosiglitazone) increased the risk of heart attacks by 43% and the risk of death from cardiovascular causes by possibly 64%. A print edition of the s... - New diet drugs Alli and Zimulti awaken memories of Fen-Phen and PPH
Jun-18-07 New York, NY This week two new diet drugs jumped into the news media. The first, Orlistat (Alli), is just now on the drugstore shelves, and the second, Rimonabant (Zimulti), is going through the FDA approval process. Will they prove to be PPH diet drugs like Fen-phen? It's been 10 years since Fen-phen was withdrawn from the market because too many peo... - April 2007 Big Pharma Litigation Update - Drugs (Part II)
Apr-12-07 Washington, DC: The anti-epileptic drug, Depakote (valproate), marketed by Abbott Laboratories, is one of the most heavily prescribed medications for off-label use. Experts say the evidence of harm caused by Depakote is just beginning to emerge. According to Harrisburg, Pennsylvania psychiatrist, Dr Stefan Kruszewski, a recognized expert on psychotropic... - FDA Advisory Committee Schedules Hearing on SSRIs and Suicide
Dec-5-06 Washington DC: The FDA's Psychopharmacologic Drugs Advisory Committee will hold a public hearing on December 13, 2006, to review the adult selective serotonin reuptake inhibitor (SSRI) studies on the increased risk of suicide associated with the antidepressants. The panel is expected to vote on whether the risk of suicidality in adults should be inclu... - FDA Pulls Zantac off Shelves
Jul-6-20 Washington, DC On April 1, the federal Food and Drug Administration asked manufacturers to withdraw Zantac and all other prescription and over-the-counter ranitidine drugs from the market immediately. It has also advised those who use OTC ranitidine medications to stop taking them immediately and patients with ranitidine prescriptions to speak with their... - Zantac Cancer Lawsuits Move to MDL Phase
Mar-20-20 West Palm Beach, FL Zantac cancer lawsuits will be consolidated in multidistrict litigation in the U.S. District Court for the Southern District of Florida. At the time of its formation on February 6, the MDL included 15 cases. An additional 126 cases were pending in 21 districts nationwide, and more plaintiffs are expected to join. The consolidated la... - New Research: Brief Heat Exposure Increases Zantac Cancer Odds
Jan-14-20 Washington, DC Emery Pharma, a California-based testing laboratory has reported that Zantac appears to produce unacceptably high levels of cancer-causing N-Nitrosodimethylamine (NDMA) when exposed to heat for as little as five days. Brief periods of modestly inadequate temperature control can easily occur during transport, storage or even in consumer&rsq... - Judge Denies GlaxoSmithKline Motion to Dismiss Lawsuits
Jan-27-16 New York, NY: A judge has reportedly denied GlaxoSmithKline’s motion to dismiss Zofran lawsuits , which alleged the morning sickness drug caused birth defects in infants exposed to the medication prior to birth. Plaintiffs in the Zofran side effects lawsuits argued it’s too early to dismiss the lawsuits because no discovery has happened yet,... - Mother “Channeling Anger into a Zofran Lawsuit”
Sep-7-15 New York, NY At least three dozen lawsuits claim that Zofran used during pregnancy caused children to be born with birth defects. The birth defects range from cleft palate to spina bifida and the most recent - a missing kidney. But every lawsuit is similar in its allegations. And every mother said that, had she known Zofran can cause birth defects, she... - GlaxoSmithKline Fined Again—The Cost of Doing Business?
Jun-26-14 It is seen as the cost of doing business. It may be illegal, but is also highly profitable, so why stop? That seems to be the attitude of many pharmaceutical companies - and the latest proof of this comes in the form of a $105 million fine leveled against GlaxoSmithKline Plc. (GSK). The California Attorney General Kamala Harris announced the fine saying h... - Lights, Action, Camera on Whistleblowers in 2011?
Jan-8-11 Washington, DC For many people, Cheryl Eckard became a celebrity after 60 minutes profiled the whistleblower in a sensational story that likely started the year off badly for GlaxoSmithKline (GSK). Lawyers and Settlements has been watching the qui tam whistleblower lawsuit unfold since last October , when we reported on the whistleblower lawsuit a... - British Medical Journal: Pull Avandia from Market
Sep-20-10 London, England The British Medical Journal recently said that the diabetes drug Avandia , made by GlaxoSmithKline, should be pulled from the market and, in fact, should never have been licensed at all. The journal found that the panel that had approved the medication prior to its entry into the European Union market in 2000 had concerns about pote...